## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.23 indicates fundamental undervaluation. Quality metrics strong (ROE 41%, ROA 13%). Consistent execution (4/4 quarters beat estimates). Caution: declining volume (40% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($117.90)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs**
- Source: Insider Monkey | 20251230T174200 | Bullish | Relevance: 100%
- Gilead Sciences, Inc. (NASDAQ:GILD) has announced a three-year agreement with the US government to lower drug costs for Americans, aligning with President Trump's pricing strategy. This initiative emphasizes US-based innovation and affordability and complements Gilead's partnership with the US Department of State to provide HIV prevention medicine at no profit in affected countries. The company also plans to invest $32 billion in US manufacturing, R&D, and infrastructure, expecting significant economic value and job creation.

**2. Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for recurrent genital herpes**
- Source: Medical Dialogues | 20251228T080818 | Bullish | Relevance: 100%
- Gilead Sciences has exercised its option to exclusively license Assembly Biosciences' helicase-primase inhibitor programs for recurrent genital herpes, including investigational candidates ABI-1179 and ABI-5366. This collaboration aims to develop novel treatments for genital herpes, a condition lacking new therapies for over 25 years. Assembly Bio will receive a $35 million payment, with potential for further regulatory and commercial milestones.

**3. Daniel Patrick O'day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock**
- Source: MarketBeat | 20251230T223353 | Somewhat-Bearish | Relevance: 100%
- Gilead Sciences CEO Daniel Patrick O'day sold 10,000 shares of company stock on December 29th for over $1.2 million, reducing his stake by 1.73%. This sale follows a pattern of monthly 10,000 share disposals by O'day. Despite insider selling, Gilead's fundamentals remain strong, with solid Q3 results, a declared dividend, and a "Moderate Buy" analyst consensus.

**4. Abacus FCF Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251230T081818 | Somewhat-Bullish | Relevance: 100%
- Abacus FCF Advisors LLC has reduced its stake in Gilead Sciences, Inc. by 16.0%, selling 26,340 shares but still holding 138,674 shares valued at $15.39 million. Despite this reduction, Gilead remains the firm's 24th largest holding. Concurrently, other institutions like Norges Bank and Ameriprise Financial Inc. have significantly increased their positions in the biopharmaceutical company, bringing institutional ownership to approximately 83.67%.

**5. Is Gilead Sciences (GILD) An Affordable Healthcare Stocks to Invest In?**
- Source: Insider Monkey | 20251229T235900 | Bullish | Relevance: 100%
- Gilead Sciences (GILD) is highlighted as an affordable healthcare stock, having recently licensed Assembly Bio's herpes simplex virus (HSV) helicase-primase inhibitor programs. These programs, which include investigational candidates ABI-1179 and ABI-5366, aim to address unmet needs in treating recurrent genital herpes with novel long-acting inhibitors. Despite Gilead's potential, the article suggests that some AI stocks may offer greater promise for higher returns and limited downside risk.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $151 | $147 | +3% |
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($10.00M) |
| Sells | 13 ($5.91M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $5.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.23 indicates undervaluation relative to growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $152.8B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.23 |
| Forward P/E | 14.1 |
| Current P/E | 15.1 |
| YoY Growth | 7.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 3.4pp (needs >4.0% for momentum thesis). MRS_5 (-0.8%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 50. Volume at 40% of 20MA suggests lack of conviction. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.65% (CS: 60) | Neutral |
| RSI_14 | 50.3 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.084x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $123.18
- **Stop Loss:** $117.90 (4.3% risk)
- **Target:** $133.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 249
- **Position Value:** $30,671.82
- **Portfolio %:** 30.67%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*